Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NOVAVAX Reports Fourth Quarter and 2011 Year-End Financial Results

Abstract:
Novavax, Inc. (Nasdaq:NVAX) today announced financial results for the fourth quarter and year ended December 31, 2011.

NOVAVAX Reports Fourth Quarter and 2011 Year-End Financial Results

Rockville, MD | Posted on March 10th, 2012

For the fourth quarter of 2011, Novavax reported a net loss of $3.7 million, or $0.03 per share, compared to a net loss of $6.3 million, or $0.06 per share, in the fourth quarter of 2010. For 2011, the company reported a net loss of $19.4 million, or $0.17 per share, compared to a net loss of $35.7 million, or $0.34 per share, for 2010. The decrease in the net loss in 2011 compared to 2010 was primarily due to revenue recognized under the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) agreement, as well as lower spending as a result of fewer on-going clinical trials during 2011.

At December 31, 2011, Novavax had cash, cash equivalents and short-term investments of $18.3 million compared to $31.7 million at December 31, 2010.

Stanley C. Erck, President and Chief Executive Officer of Novavax, stated: "The past year has been transformational for our company as we landed two government contracts and one commercial partnership, and from a financial perspective reduced our net loss by almost fifty percent. We now have three promising vaccine candidates in clinical testing, funding from BARDA to take our seasonal and pandemic influenza vaccines through late-stage testing and BLA filing, a new research program in foot-and-mouth disease, advancing international collaborations in India and Asia and new U.S. manufacturing and office facilities to support our expansion and commercial plans. In addition, we have made several significant key hires to strengthen our team in pivotal functional areas of the company including clinical, regulatory, manufacturing and process development. With the caliber of people we are attracting to Novavax, I am confident that we now have the expertise, commitment and vision to execute our vaccine development programs successfully. These achievements reflect the significant progress we have made to realize the clinical and commercial potential of our virus-like particle (VLP) and recombinant nanoparticle vaccine technology platforms."

Key highlights of 2011:

In February 2011, we were awarded a $97 million 3-year contract from BARDA to develop and scale-up our seasonal and pandemic influenza vaccine candidates. BARDA has an option to extend our contract for an additional $82 million over a 2-year extension period. During 2011, we recognized revenue of approximately $15 million, made significant progress in product characterization and production scale-up and are progressing forward with our multi-year clinical-development program.

We conducted a Phase I clinical trial testing our vaccine candidate against respiratory syncytial virus (RSV) in 150 healthy adults in a blinded, placebo-controlled, escalating-dose study. In October 2011, we presented interim top-line data from the trial at the 5th Vaccine and ISV Annual Global Conference. The positive results were consistent with pre-clinical studies and showed that the vaccine candidate was well-tolerated, highly immunogenic and produced functional antibodies that neutralized RSV.

During 2011, the company made the following senior-executive appointments: Stanley C. Erck was named President and Chief Executive Officer, Louis Fries III M.D., was named Vice President, Clinical and Medical Affairs, Gregory Glenn, M.D., was named Senior Vice President and Chief Medical Officer, Timothy Hahn, Ph.D., was named Senior Vice President of Manufacturing and Process Development, Jane Halpern, Ph.D., was named Vice President Regulatory Affairs, Erica Shane, Ph.D., was named Vice President Process Development and Russell P. Wilson was named Senior Vice President, Business Development. In early 2012, the company appointed Mervyn L. Hamer as Vice President, Manufacturing and John A. Herrmann III, J.D. as Vice President, General Counsel and Secretary.

In February 2011, we entered into a licensing agreement with LG Life Sciences (LGLS) that allows LGLS to use our VLP technology to develop and commercialize our influenza vaccines in South Korea and certain other emerging-market countries. LGLS holds an exclusive license to our influenza VLP technology in South Korea and a non-exclusive license in the other specified countries.

In November, we announced a long-term lease arrangement to occupy 74,000 square feet of manufacturing, laboratory and office space in two facilities in Gaithersburg, MD. The main facility will become the primary commercial-scale manufacturing facility for production of the company's vaccines after moderate modifications that are expected to be completed in 2012.

CPL Biologics (CPLB), our joint venture in India with Cadila Pharmaceuticals Ltd., is developing a promising new rabies vaccine developed by Novavax for which it is now conducting toxicology studies prior to initiating human clinical trials. CPLB has also completed validation testing of its new manufacturing facility to produce clinical and commercial supplies of influenza and rabies vaccine candidates and has made excellent early-stage progress with the development of other new vaccine candidates.

In October, Novavax was awarded a $1.3 million contract with the U.S. Department of Homeland Security to develop a VLP vaccine countermeasure to protect the United States from foot-and-mouth disease (FMD), a highly contagious viral disease of livestock and a potential threat to U.S. agriculture. The company will use these funds over the next two and a half years to develop a VLP that, unlike current FMD vaccines, would not require the use of infectious FMD virus to be manufactured.

We continued to present our clinical findings at medical and scientific conferences throughout the year, including the 7th World Health Organization Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials at which we presented the final positive results of our H1N1 VLP seasonal influenza study in Mexico. We also published results from this study in the journal Vaccine and the results from our Phase I/IIa pandemic H5N1 influenza study in Journal of Virology.

Anticipated events in 2012:

In March 2012, we initiated a Phase II trial under our BARDA contract to select the optimal dose of our quadrivalent seasonal influenza VLP vaccine candidate. We also expect to initiate a dose-confirmatory Phase II trial later this year.

We expect to launch two Phase I trials of our H5N1 VLP influenza vaccine candidate utilizing multiple adjuvants under our BARDA contract.

We expect to initiate two dose-ranging Phase I/II trials of our RSV vaccine candidate in the elderly and in women of child-bearing age.

Conference Call

Novavax's management will host its quarterly conference call today at 10:00 a.m. EST today. The live conference call will be accessible on Novavax's website at www.novavax.com under "Investor Info/Events" or by telephone at 1 (877) 212-6076 (Domestic) or 1 (707) 287-9331 (International). A replay of the webcast will be available on the Novavax website for 90 days after the call and a replay of the conference call will be available beginning today at 1:00 pm through May 09, 2012. To access the replay of the conference call, dial 1 (855) 859-2056 (Domestic) or 1 (404) 537-3406 (International) and enter passcode 55983197.

####

About Novavax, Inc.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. Using innovative virus-like particle (VLP) and recombinant nanoparticle vaccine technology, combined with new and efficient manufacturing approaches, the company produces vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India and LG Life Sciences of Korea. Together, these companies have worldwide commercialization capacity and the global reach to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company's website: www.novavax.com.

Forward-Looking Statements

Statements herein relating to the future of Novavax and its ongoing development of its vaccine products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2010, and other filings from time to time filed with the Securities and Exchange Commission. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

 
NOVAVAX, INC.
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share information)
  	  	  	  	 
  	  	  	  	 
  	Three Months Ended 	Twelve Months Ended
  	December 31, 	December 31,
  	2011 	2010 	2011 	2010
  	(unaudited) 	 
Revenue 	 $ 5,845 	 $ 51 	 $ 14,688 	 $ 343
  	  	  	  	 
Costs and expenses: 	  	  	  	 
Cost of revenue 	3,206 	-  	7,003 	- 
Research and development 	4,446 	4,806 	17,885 	28,032
General and administrative 	2,453 	2,279 	11,379 	10,805
Total costs and expenses 	10,105 	7,085 	36,267 	38,837
Loss from operations 	(4,260) 	(7,034) 	(21,579) 	(38,494)
Interest income (expense), net 	28 	48 	127 	180
Other income 	26 	485 	26 	485
Change in fair value of warrant liability 	501 	(100) 	2,474 	1,671
Loss from operations before income tax 	(3,705) 	(6,601) 	(18,952) 	(36,158)
Income tax (benefit) expense 	- 	(315) 	412 	(450)
Net loss 	 $ (3,705) 	 $ (6,286) 	 $ (19,364) 	 $ (35,708)
  	  	  	  	 
Basic and diluted net loss per share 	 $ (0.03) 	 $ (0.06) 	 $ (0.17) 	 $ (0.34)
Basic and diluted weighted average number of common shares outstanding 	115,263 	110,958 	113,610 	104,768
 
SELECTED BALANCE SHEET DATA
(in thousands)
 
  	December 31,   	December 31,
  	2011 	2010
  	  	 
Cash and cash equivalents 	$ 14,104 	$ 8,061
Short-term investments 	 4,205 	 23,615
Total current assets 	 26,109 	 33,337
Working capital 	 18,530 	 23,071
Total assets 	 66,576 	 74,844
Total notes payable 	 320 	 400
Total stockholders' equity 	 53,849 	 59,050

For more information, please click here

Contacts:
Frederick W. Driscoll
VP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000

Copyright © GlobeNewswire, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

NIST offers electronics industry 2 ways to snoop on self-organizing molecules October 22nd, 2014

Journal Nanotechnology Progress International (JONPI), 2014, Volume 5, Issue 1, pp 1-24 October 22nd, 2014

TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

Nanomedicine

Journal Nanotechnology Progress International (JONPI), 2014, Volume 5, Issue 1, pp 1-24 October 22nd, 2014

TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014

‘Designer’ nanodevice could improve treatment options for cancer sufferers October 22nd, 2014

Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014

Announcements

NanoTechnology for Defense (NT4D) October 22nd, 2014

Mechanism behind nature's sparkles revealed October 22nd, 2014

TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

Financial Reports

Aspen Aerogels, Inc. Schedules Third Quarter 2014 Earnings Release and Conference Call for November 6, 2014 October 17th, 2014

Nanometrics to Announce Third Quarter Financial Results on October 28, 2014 October 8th, 2014

Harris & Harris Group Letter to Shareholders on Website August 19th, 2014

Arrowhead Reports Fiscal 2014 Third Quarter Financial Results and Provides Update on ARC-520 August 12th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE